TG Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary

• TG Therapeutics, Inc. reported quarterly adjusted earnings of 35 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of 16 cents. The mean expectation of eight analysts for the quarter was for earnings of 37 cents per share. Wall Street expected results to range from 19 cents to 63 cents per share.

• Revenue rose 60.7% to $259.94 million from a year ago; analysts expected $245.48 million.

• TG Therapeutics, Inc.'s reported EPS for the quarter was 35 cents​.

• The company reported quarterly net income of $55.46 million.

• TG Therapeutics, Inc. shares had risen by 7.3% this quarter and gained 100.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for TG Therapeutics, Inc. is $76.50, about 21.8% above its last closing price of $59.83

This summary was machine generated from LSEG data November 9 at 02:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)